SG Americas Securities
VRTX icon

SG Americas Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

SG Americas Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
+10,000
New +$4.43M ﹤0.01% 3097
2026
Q1 		– Sell
-55,100
Closed -$297K – 3750
2025
Q4 		$297K Buy
+55,100
New +$23.7M ﹤0.01% 2760
2024
Q4 		– Sell
-2,400
Closed -$178K – 3662
2024
Q3 		$178K Buy
2,400
+900
+60% +$432K ﹤0.01% 2598
2024
Q2 		$138K Sell
1,500
-7,100
-83% -$3.08M ﹤0.01% 2372
2024
Q1 		$465K Sell
8,600
-45,400
-84% -$19.2M ﹤0.01% 1467
2023
Q4 		$1.26M Sell
54,000
-5,600
-9% -$2.07M 0.01% 899
2023
Q3 		$593K Buy
59,600
+54,600
+1,092% +$19.1M 0.01% 1639
2023
Q2 		$156K Sell
5,000
-83,000
-94% -$28M ﹤0.01% 1901
2023
Q1 		$1.17M Buy
88,000
+78,000
+780% +$23.4M 0.01% 1038
2022
Q4 		$6K Buy
10,000
+2,000
+25% +$610K ﹤0.01% 2986
2022
Q3 		$281K Sell
8,000
-5,000
-38% -$1.44M ﹤0.01% 2042
2022
Q2 		$482K Sell
13,000
-87,500
-87% -$23.4M 0.01% 1993
2022
Q1 		$3.03M Buy
100,500
+85,500
+570% +$20.3M 0.02% 661
2021
Q4 		$692K Buy
+15,000
New +$2.92M ﹤0.01% 1913
2020
Q4 		– Sell
-40,000
Closed -$56K – 3492
2020
Q3 		$56K Buy
+40,000
New +$11M ﹤0.01% 2513
2016
Q4 		– Sell
-12,000
Closed -$11K – 3492
2016
Q3 		$11K Hold
12,000
– – ﹤0.01% 3276
2016
Q2 		$17K Hold
12,000
– – ﹤0.01% 2516
2016
Q1 		$26K Hold
12,000
– – ﹤0.01% 2821
2015
Q4 		$263K Buy
+12,000
New +$1.45M ﹤0.01% 1959
2015
Q3 		– Sell
-12,000
Closed -$290K – 2722
2015
Q2 		$290K Hold
12,000
– – ﹤0.01% 1799
2015
Q1 		$276K Buy
+12,000
New +$1.44M ﹤0.01% 1728

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SG Americas Securities's VRTX Position: Q2 2026 in Review

SG Americas Securities increased its Vertex Pharmaceuticals (VRTX) stake by 819% in Q2 2026, buying an estimated $207M and bringing the position to 523,720 shares worth $260M. The position accounts for 0.15% of the portfolio, ranked #103.

SG Americas Securities first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • SG Americas Securities held 523,720 shares of Vertex Pharmaceuticals worth $260M as of Q2 2026.
  • SG Americas Securities bought 466,738 Vertex Pharmaceuticals shares in Q2 2026, an estimated $207M.
  • Vertex Pharmaceuticals made up 0.15% of SG Americas Securities's portfolio in Q2 2026, its #103 holding.
  • SG Americas Securities first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.